On February 23, 2023, Eko, a digital health company employing artificial intelligence (AI) to combat heart and lung diseases, announced the launch of the SENSORATM Cardiac Disease Detection Platform. The platform features AI that detects structural murmurs, an indication of valvular heart disease, and Care Pathway Analytics software, which offers downstream visibility and metrics for the patient's journey along the healthcare system.
SENSORA™ is a detection platform for cardiovascular disease that utilizes digital stethoscopes to capture and analyze heart sounds and electrical signals. This platform leverages the latest advancements in machine learning to continue expanding the platform and develop new use cases for cardiac conditions.
Over 8 million Americans are diagnosed with clinically significant valvular heart disease (VHD), and one in ten older adults have a chance to develop it. Unfortunately, more than half (57%) of significant VHD cases in this population go undetected. Left untreated, VHD can cause blood clots, heart failure, and mortality. With SENSORA™'s FDA-cleared structural murmur detection, primary care physicians more than double their likelihood of detecting significant VHD.
SENSORA™ Care Pathway Analytics can aid in crucial decision-making by identifying care gaps to convert them into improved operational efficiencies, ultimately improving patient and clinician satisfaction. In addition, the platform provides downstream visibility for those with identified structural murmurs by tracking clinical outcomes, patient flows, and economics throughout the care continuum.
Eko currently offers five FDA 510(k) cleared digital solutions and is developing two novel machine-learning algorithms that use electrocardiogram (ECG) and heart sound data. These algorithms include "ELEFT," which detects low ejection fraction in heart failure patients, and another algorithm that detects and stratifies pulmonary hypertension. The company is dedicated to developing advanced solutions that fulfill the needs of patients and clinicians. By enabling early detection of heart and lung diseases, the company can help save lives.
About Eko
Eko, a digital health company based in Oakland (California), is evolving how healthcare providers diagnose and monitor heart and lung disease with its suite of innovative digital tools, patient and provider software, and AI-driven analysis. Its FDA-approved platform is employed by many healthcare professionals worldwide, enabling them to optimize detection, diagnosis, and treatment management, and ultimately provide the best care possible to their patients. It has received over $125 million in funding from Highland Capital Partners, Questa Capital, DigiTx Partners, NTTVC, Artis Ventures, Mayo Clinic, Sutter Health, and others.